These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10758313)

  • 21. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
    Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary morbidity with a modified peripheral loading technique of transperineal (125)i prostate implantation.
    Brown D; Colonias A; Miller R; Benoit R; Cohen J; Arshoun Y; Galloway M; Karlovits S; Wu A; Johnson M; Quinn A; Kalnicki S
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):353-60. PubMed ID: 10802359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
    Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of urinary symptoms after 125iodine prostate brachytherapy.
    Kelly K; Swindell R; Routledge J; Burns M; Logue JP; Wylie JP
    Clin Oncol (R Coll Radiol); 2006 May; 18(4):326-32. PubMed ID: 16703751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serial changes of international prostate symptom score following I-125 prostate brachytherapy.
    Ohashi T; Yorozu A; Toya K; Saito S; Momma T
    Int J Clin Oncol; 2006 Aug; 11(4):320-5. PubMed ID: 16937307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of radiation dose to the urethra on brachytherapy-related dysuria.
    Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Lief JH; Reed DJ
    Brachytherapy; 2005; 4(1):45-50. PubMed ID: 15737906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
    Williams SG; Millar JL; Duchesne GM; Dally MJ; Royce PL; Snow RM
    Radiother Oncol; 2004 Oct; 73(1):33-8. PubMed ID: 15465143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors predicting for urinary incontinence after prostate brachytherapy.
    McElveen TL; Waterman FM; Kim H; Dicker AP
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):81-8. PubMed ID: 14697424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy.
    Ferro A; Bae HJ; Yenokyan G; Le Y; McNutt T; Mian O; Gergis C; Haviland C; DeWeese TL; Song DY
    Brachytherapy; 2018; 17(2):313-318. PubMed ID: 29174937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erectile function after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Galbreath RW; Stipetich RL; Abel LJ; Lief JH
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):893-902. PubMed ID: 11958881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma.
    Wehle MJ; Lisson SW; Buskirk SJ; Broderick GA; Young PR; Igel TC
    Mayo Clin Proc; 2004 Mar; 79(3):314-7. PubMed ID: 15008604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy.
    Crook J; Toi A; McLean M; Pond G
    Brachytherapy; 2002; 1(3):131-7. PubMed ID: 15090275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
    Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
    Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy.
    Bittner N; Merrick GS; Wallner KE; Lief JH; Butler WM; Galbreath RW
    Brachytherapy; 2007; 6(4):258-66. PubMed ID: 17991623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selecting patients with pretreatment postvoid residual urine volume less than 100 mL may favorably influence brachytherapy-related urinary morbidity.
    Beekman M; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW
    Urology; 2005 Dec; 66(6):1266-70. PubMed ID: 16360455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study.
    Henderson A; Ismail AK; Cunningham M; Aldridge S; Loverock L; Langley SE; Laing RW
    Clin Oncol (R Coll Radiol); 2004 Apr; 16(2):95-104. PubMed ID: 15074730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
    Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term urinary sequelae following 125iodine prostate brachytherapy.
    Crook J; Fleshner N; Roberts C; Pond G
    J Urol; 2008 Jan; 179(1):141-5; discussion 146. PubMed ID: 17997424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urethral dose and increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer.
    Murakami N; Itami J; Okuma K; Marino H; Nakagawa K; Ban T; Nakazato M; Kanai K; Naoi K; Fuse M
    Strahlenther Onkol; 2008 Oct; 184(10):515-9. PubMed ID: 19016040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.